Busey Bank Decreases Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Busey Bank lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,209 shares of the medical equipment provider’s stock after selling 140 shares during the quarter. Busey Bank’s holdings in Zimmer Biomet were worth $550,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in ZBH. Dunhill Financial LLC increased its stake in shares of Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 218 shares in the last quarter. Ashton Thomas Securities LLC purchased a new stake in Zimmer Biomet during the 3rd quarter worth approximately $28,000. Bangor Savings Bank acquired a new position in shares of Zimmer Biomet during the third quarter valued at approximately $31,000. Brooklyn Investment Group purchased a new position in shares of Zimmer Biomet in the third quarter valued at approximately $35,000. Finally, Quarry LP acquired a new stake in shares of Zimmer Biomet in the second quarter worth approximately $53,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Down 0.4 %

NYSE:ZBH opened at $110.63 on Friday. Zimmer Biomet Holdings, Inc. has a 52 week low of $100.67 and a 52 week high of $133.90. The stock’s fifty day moving average is $107.91 and its two-hundred day moving average is $108.22. The stock has a market capitalization of $22.02 billion, a price-to-earnings ratio of 21.03, a price-to-earnings-growth ratio of 1.90 and a beta of 1.02. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting analysts’ consensus estimates of $1.74. The company had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. Zimmer Biomet’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same period last year, the business posted $1.65 EPS. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Monday, December 30th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 18.25%.

Analyst Ratings Changes

Several research analysts recently commented on the company. Truist Financial increased their price objective on Zimmer Biomet from $117.00 to $118.00 and gave the company a “hold” rating in a research note on Wednesday, December 18th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Wednesday. Stifel Nicolaus upped their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research note on Thursday, January 23rd. BTIG Research decreased their target price on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a research note on Thursday, October 3rd. Finally, Royal Bank of Canada upped their price target on Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a research report on Monday, November 4th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $124.11.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.